Sympathetic activation in heart failure: A target of therapeutic approaches

被引:2
|
作者
P. Schnabel
M. Böhm
机构
[1] Klinik III für Innere Medizin der Universität zu Köln,
[2] Joseph-Stelzmann-Str. 9,undefined
[3] D-50924 Köln,undefined
[4] Germany,undefined
来源
Zeitschrift für Kardiologie | 1999年 / 88卷 / Suppl 3期
关键词
Key words Heart failure – neuroendocrine activation – sympathetic nervous system – signal transduction;
D O I
10.1007/s003920050575
中图分类号
学科分类号
摘要
In heart failure, decreased cardiac output leads to a number of adaptive mechanisms. Among these, neuroendocrine activation including activation of the renin-angiotensin-aldosterone system, augmentation of vasopressin and endothelin release, and activation of the sympathetic nervous system occur. The increase of adrenergic drive is characterized by decreased baroreceptor sensitivity, increased plasma norepinephrine levels and cardiac norepinephrine spillover, and desensitization of postsynaptic β-adrenergic signal transduction. While increased sympathetic drive initially helps to maintain contractile performance of the damaged heart, the above changes chronically result in catecholamine refractoriness and are associated with a poor prognosis.
引用
收藏
页码:S005 / S011
相关论文
共 50 条
  • [21] Capillaries as a Therapeutic Target for Heart Failure
    Yoshida, Yohko
    Shimizu, Ippei
    Minamino, Tohru
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2022, 29 (07) : 971 - 988
  • [22] β-Arrestin as a Therapeutic Target in Heart Failure
    Boussi, Leora
    Frishman, William H.
    CARDIOLOGY IN REVIEW, 2021, 29 (05) : 223 - 229
  • [23] Apoptosis as a therapeutic target in heart failure
    Das, Manika
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2007, 293 (03): : H1322 - H1323
  • [24] AMPK activation, a preventive therapeutic target in the transition from cardiac injury to heart failure
    Beauloye, Christophe
    Bertrand, Luc
    Horman, Sandrine
    Hue, Louis
    CARDIOVASCULAR RESEARCH, 2011, 90 (02) : 224 - 233
  • [25] Sympathetic activation in congestive heart failure: an updated overview
    Grassi, Guido
    Quarti-Trevano, Fosca
    Esler, Murray D.
    HEART FAILURE REVIEWS, 2021, 26 (01) : 173 - 182
  • [26] Sympathetic nerve activation in heart failure and iron deficiency
    Baker, R. Richard
    Adams, Z. H.
    Hope, K. A.
    Hart, E. C.
    Nightingale, A. K.
    EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 : 169 - 170
  • [27] EXCESSIVE SYMPATHETIC ACTIVATION IN HEART FAILURE ASSOCIATED WITH ANEMIA
    Franchitto, N.
    Despas, F.
    Labrunee, M.
    Boveda, S.
    Galinier, M.
    Senard, J. M.
    Pathak, A.
    JOURNAL OF HYPERTENSION, 2010, 28 : E528 - E528
  • [28] Sympathetic activation in heart failure and its treatment with β-blockade
    Pepper, GS
    Lee, RW
    ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (03) : 225 - 234
  • [29] Sympathetic activation in congestive heart failure: an updated overview
    Guido Grassi
    Fosca Quarti-Trevano
    Murray D. Esler
    Heart Failure Reviews, 2021, 26 : 173 - 182
  • [30] Excessive sympathetic activation in heart failure with chronic renal failure: role of chemorellex activation
    Despas, F.
    Detis, N.
    Labrunee, M.
    Franchitto, N.
    Galinier, M.
    Senard, J. M.
    Pathak, A.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2010, 24 : 21 - 22